BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 31492693)

  • 1. Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
    Bissada JE; Truong V; Abouda AA; Wines KJ; Crouch RD; Jackson KD
    Drug Metab Dispos; 2019 Nov; 47(11):1257-1269. PubMed ID: 31492693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P450 3A4 and CYP3A5-Catalyzed Bioactivation of Lapatinib.
    Towles JK; Clark RN; Wahlin MD; Uttamsingh V; Rettie AE; Jackson KD
    Drug Metab Dispos; 2016 Oct; 44(10):1584-97. PubMed ID: 27450182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interindividual Variability in Cytochrome P450 3A and 1A Activity Influences Sunitinib Metabolism and Bioactivation.
    Burnham EA; Abouda AA; Bissada JE; Nardone-White DT; Beers JL; Lee J; Vergne MJ; Jackson KD
    Chem Res Toxicol; 2022 May; 35(5):792-806. PubMed ID: 35484684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Studies on the role of metabolic activation in tyrosine kinase inhibitor-dependent hepatotoxicity: induction of CYP3A4 enhances the cytotoxicity of lapatinib in HepaRG cells.
    Hardy KD; Wahlin MD; Papageorgiou I; Unadkat JD; Rettie AE; Nelson SD
    Drug Metab Dispos; 2014 Jan; 42(1):162-71. PubMed ID: 24191259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interaction of lapatinib with cytochrome P450 3A5.
    Chan EC; New LS; Chua TB; Yap CW; Ho HK; Nelson SD
    Drug Metab Dispos; 2012 Jul; 40(7):1414-22. PubMed ID: 22511346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detoxication versus Bioactivation Pathways of Lapatinib In Vitro: UGT1A1 Catalyzes the Hepatic Glucuronidation of Debenzylated Lapatinib.
    Nardone-White DT; Bissada JE; Abouda AA; Jackson KD
    Drug Metab Dispos; 2021 Mar; 49(3):233-244. PubMed ID: 33376146
    [No Abstract]   [Full Text] [Related]  

  • 7. Selective mechanism-based inactivation of CYP3A4 by CYP3cide (PF-04981517) and its utility as an in vitro tool for delineating the relative roles of CYP3A4 versus CYP3A5 in the metabolism of drugs.
    Walsky RL; Obach RS; Hyland R; Kang P; Zhou S; West M; Geoghegan KF; Helal CJ; Walker GS; Goosen TC; Zientek MA
    Drug Metab Dispos; 2012 Sep; 40(9):1686-97. PubMed ID: 22645092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of CYP3A5 expression on vincristine metabolism with human liver microsomes.
    Dennison JB; Jones DR; Renbarger JL; Hall SD
    J Pharmacol Exp Ther; 2007 May; 321(2):553-63. PubMed ID: 17272675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relative contributions of cytochrome CYP3A4 versus CYP3A5 for CYP3A-cleared drugs assessed in vitro using a CYP3A4-selective inactivator (CYP3cide).
    Tseng E; Walsky RL; Luzietti RA; Harris JJ; Kosa RE; Goosen TC; Zientek MA; Obach RS
    Drug Metab Dispos; 2014 Jul; 42(7):1163-73. PubMed ID: 24737844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
    Mouly SJ; Matheny C; Paine MF; Smith G; Lamba J; Lamba V; Pusek SN; Schuetz EG; Stewart PW; Watkins PB
    Clin Pharmacol Ther; 2005 Dec; 78(6):605-18. PubMed ID: 16338276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of human intestinal wall metabolism by macrolide antibiotics: effect of clarithromycin on cytochrome P450 3A4/5 activity and expression.
    Pinto AG; Wang YH; Chalasani N; Skaar T; Kolwankar D; Gorski JC; Liangpunsakul S; Hamman MA; Arefayene M; Hall SD
    Clin Pharmacol Ther; 2005 Mar; 77(3):178-88. PubMed ID: 15735612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sorafenib and sunitinib, two anticancer drugs, inhibit CYP3A4-mediated and activate CY3A5-mediated midazolam 1'-hydroxylation.
    Sugiyama M; Fujita K; Murayama N; Akiyama Y; Yamazaki H; Sasaki Y
    Drug Metab Dispos; 2011 May; 39(5):757-62. PubMed ID: 21266595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: impact on modeling CYP3A-mediated drug-drug interactions.
    Shirasaka Y; Chang SY; Grubb MF; Peng CC; Thummel KE; Isoherranen N; Rodrigues AD
    Drug Metab Dispos; 2013 Aug; 41(8):1566-74. PubMed ID: 23723360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of T-5 N-oxide formation as the first highly selective measure of CYP3A5 activity.
    Li X; Jeso V; Heyward S; Walker GS; Sharma R; Micalizio GC; Cameron MD
    Drug Metab Dispos; 2014 Mar; 42(3):334-42. PubMed ID: 24335391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct and Sequential Bioactivation of Pemigatinib to Reactive Iminium Ion Intermediates Culminates in Mechanism-Based Inactivation of Cytochrome P450 3A.
    Tang LWT; Wei W; Verma RK; Koh SK; Zhou L; Fan H; Chan ECY
    Drug Metab Dispos; 2022 May; 50(5):529-540. PubMed ID: 35153194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
    Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
    Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Azamulin to Determine the Contribution of CYP3A4/5 to Drug Metabolic Clearance Using Human Hepatocytes.
    Chanteux H; Rosa M; Delatour C; Nicolaï J; Gillent E; Dell'Aiera S; Ungell AL
    Drug Metab Dispos; 2020 Sep; 48(9):778-787. PubMed ID: 32532738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
    Klees TM; Sheffels P; Thummel KE; Kharasch ED
    Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib.
    Teng WC; Oh JW; New LS; Wahlin MD; Nelson SD; Ho HK; Chan EC
    Mol Pharmacol; 2010 Oct; 78(4):693-703. PubMed ID: 20624855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.